NASDAQ:DNLI

Denali Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy DNLI

*Your capital is at risk

$24.77

+0.720 (+2.99%)

At Close: Jun 23, 2026

Denali Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -46.02. In total, the insiders bought 53.81M and sold 1.16M DNLI shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-46.02
● Buy	53.81M shares
● Sell	1.16M shares
88% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Apr 10, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -46.02. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (88% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 03, 2026 Buy	Non- Qualified Stock Option (right to buy) A-Award	Baker Bros. Advisors Lp Director	Director	19 226 Value: $378.0K
Jun 03, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Baker Bros. Advisors Lp Director	Director	19 226 Value: $378.0K
Jun 03, 2026 Buy	Common Stock A-Award	Baker Bros. Advisors Lp Director	Director	6 408 Value: $126.0K
Jun 03, 2026 Buy	Common Stock A-Award	Baker Bros. Advisors Lp Director	Director	6 408 Value: $126.0K
Jun 03, 2026 Buy	Stock Option (right to buy) A-Award	Cook Jennifer E. Director	Director	19 226 Value: $378.0K
Jun 03, 2026 Buy	Stock Option (right to buy) A-Award	Krognes Steve E. Director	Director	19 226 Value: $378.0K
Jun 03, 2026 Buy	Common Stock A-Award	Krognes Steve E. Director	Director	6 408 Value: $126.0K
Jun 03, 2026 Buy	Stock Option (right to buy) A-Award	Klein Peter S Director	Director	19 226 Value: $378.0K
Jun 03, 2026 Buy	Common Stock A-Award	Klein Peter S Director	Director	6 408 Value: $126.0K
Jun 03, 2026 Buy	Stock Option (right to buy) A-Award	Flatley Jay T Director	Director	19 226 Value: $378.0K
Jun 03, 2026 Buy	Common Stock A-Award	Flatley Jay T Director	Director	6 408 Value: $126.0K
Jun 03, 2026 Buy	Common Stock A-Award	Schenkein David P Director	Director	6 408 Value: $126.0K
Jun 03, 2026 Buy	Stock Option (right to buy) A-Award	Schenkein David P Director	Director	19 226 Value: $378.0K
Jun 03, 2026 Buy	Common Stock A-Award	Thornberry Nancy Director	Director	6 408 Value: $126.0K
Jun 03, 2026 Buy	Stock Option (right to buy) A-Award	Thornberry Nancy Director	Director	19 226 Value: $378.0K
Jun 03, 2026 Buy	Stock Option (right to buy) A-Award	Van Hauwermeiren Timothy Director	Director	19 226 Value: $378.0K
Jun 03, 2026 Buy	Common Stock A-Award	Van Hauwermeiren Timothy Director	Director	6 408 Value: $126.0K
Jun 03, 2026 Buy	Common Stock A-Award	Cook Jennifer E. Director	Director	6 408 Value: $126.0K
Apr 10, 2026 Buy	Common Stock	Chin Peter Scott Chief Medical Officer	Officer	0 Value: $0
Apr 10, 2026 Buy	Stock Option (right to buy)	Chin Peter Scott Chief Medical Officer	Officer	14 250 Value: $1.14M
Apr 10, 2026 Buy	Stock Option (right to buy)	Chin Peter Scott Chief Medical Officer	Officer	35 100 Value: $870.8K
Apr 10, 2026 Buy	Stock Option (right to buy)	Chin Peter Scott Chief Medical Officer	Officer	43 000 Value: $959.3K
Apr 10, 2026 Buy	Common Stock	Chin Peter Scott Chief Medical Officer	Officer	0 Value: $0
Apr 10, 2026 Buy	Stock Option (right to buy)	Chin Peter Scott Chief Medical Officer	Officer	13 000 Value: $614.5K
Apr 10, 2026 Buy	Stock Option (right to buy)	Chin Peter Scott Chief Medical Officer	Officer	10 250 Value: $345.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT DENALI THERAPEUTICS INC.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ...

Read Full Profile Here